Format

Send to

Choose Destination
J Hematol Oncol. 2012 Feb 14;5:3. doi: 10.1186/1756-8722-5-3.

Current management and novel agents for malignant melanoma.

Author information

1
Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, New York 10595, USA.

Abstract

Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.

PMID:
22333219
PMCID:
PMC3293076
DOI:
10.1186/1756-8722-5-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center